Phillips-Medisize announced that it has enhanced its capabilities to provide better ways of partnering with customers.
The company currently offers end-to-end services, electrical integration and technology accelerators with integrated quality systems and a global footprint that allows for accelerated time to market, reduced risk and maximized development resources.
“At Phillips-Medisize, we believe innovation grows at the intersection of market needs and emerging technologies,” Matt Jennings, CEO and president of Phillips-Medisize, said. “By driving innovation at every level and project phase, we help customers bring better drug delivery devices and connected health solutions to market swiftly, with increased confidence.”
Phillips-Medisize has expertise in electronics hardware, software engineering, PCBA manufacturing and assembly and has the capabilities to partner with customers to create connection health solutions. The connected health platforms are used to collect patient data and give instruction content to patients, healthcare providers, caregivers and payers.
“Phillips-Medisize pushed the boundaries of technology-driven innovation to give their customers a competitive edge in the design, development and commercial manufacturing of differentiated drug delivery devices and connected health solutions,” said Joe Nelligan, president and chief operating officer of Phillips-Medisize’s parent company Molex.
